OBJECTIVE: To evaluate both the patterns of prescription of @entity342 deprivation therapy (ADT) in @entity1 with @entity263 ( @entity263 ) and the adherence to European Association of Urology (EAU) guidelines for ADT prescription. METHODS: The Choosing Treatment for @entity263 (CHOICE) study was an Italian multicentre cross-sectional study conducted between December 2010 and January 2012. A total of 1 386 @entity1 , treated with ADT for @entity263 (first prescription or renewal of ADT), were selected. With regard to the EAU guidelines on ADT, the cohort was categorized into discordant ADT (Group A) and concordant ADT (Group B). RESULTS: The final cohort included 1 075 @entity1 with a geographical distribution including North Italy (n = 627, 58.3%), Central Italy (n = 233, 21.7%) and South Italy (n = 215, 20.0%). In the category of @entity1 treated with primary ADT, a total of 125 @entity1 (56.3%) were classified as low risk according to D'Amico classification. With regard to the EAU guidelines, 285 (26.51%) and 790 @entity1 (73.49%) were classified as discordant (Group A) and concordant (Group B), respectively. In Group A, @entity1 were more likely to receive primary ADT (57.5%, 164/285 @entity1 ) than radical prostatectomy (RP; 30.9%, 88/285 @entity1 ), @entity1161 ( @entity1161 ; 6.7%, 19/285 @entity1 ) or RP + @entity1161 (17.7%, 14/285 @entity1 ; P < 0.01). Multivariate logistic regression analysis, adjusted for clinical and pathological variables, showed that @entity1 from Central Italy (odds ratio [OR] 2.86; P < 0.05) and South Italy (OR 2.65; P < 0.05) were more likely to receive discordant ADT. CONCLUSION: EAU guideline adherence for ADT was low in Italy and was influenced by geographic area. Healthcare providers and urologists should consider these results in order to quantify the inadequate use of ADT and to set policy strategies to overcome this risk.

Patterns of prescription and adherence to European Association of Urology guidelines on @entity342 deprivation therapy in @entity263 : an Italian multicentre cross-sectional analysis from the Choosing Treatment for XXXX (CHOICE) study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity263 :: ('MESH:D011471', 'Disease') :: ['PCa', 'prostate cancer', 'Prostate Cancer'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen'] @entity1161 :: ('MESH:D011832', 'Disease') :: ['radiation therapy', 'RT']
@entity263 :: (MESH:D011471,Disease) :: ['Prostate Cancer']
